{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Pulmonary fibrosis', \"Raynaud's phenomenon\", 'Sarcoidosis', 'Pulmonary sarcoidosis', \"Sjogren's syndrome\", 'Epidermal necrosis', 'Skin necrosis', 'Stomatitis', 'Systemic inflammatory response syndrome', 'Thyroid dermatopathy', 'Autoimmune thyroid disorder', 'Thyroid disorder', 'Autoimmune thyroiditis', 'Immune-mediated thyroiditis', 'Thyroiditis', 'Thyroiditis acute', 'Thyroiditis chronic', 'Thyroiditis fibrous chronic', 'Thyroiditis subacute', 'Trigeminal nerve paresis', 'Diabetes mellitus', 'Diabetic ketoacidosis', 'Latent autoimmune diabetes in adults', 'Type 1 diabetes mellitus', 'Regeneron Pharmaceuticals, Inc.', 'Page 142 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1. Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Autoimmune uveitis', 'Immune-mediated uveitis', 'Uveitis', 'Vasculitis', 'Vitiligo', 'Vocal cord paralysis', 'Regeneron Pharmaceuticals, Inc.', 'Page 143 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'APPENDIX 4. FACTORS TO CONSIDER IN ASSESSING THE', 'RELATIONSHIP OF ADVERSE EVENTS TO STUDY', 'DRUG, STUDY CONDUCT, INFUSION PROCEDURE, OR', 'STUDY PROCEDURE', 'Is there a reasonable possibility that the event may have been caused by the study drug, study', 'conduct, infusion procedure, or study procedure?', 'No:', 'due to external causes such as environmental factors or other treatment(s) being', 'administered', \"due to the patient's disease state or clinical condition\", 'do not follow a reasonable temporal sequence following the time of administration of', 'the dose of study drug', 'do not reappear or worsen when dosing with study drug or study procedure resumed', 'are not a suspected response to the study drug or study procedure based upon', 'preclinical data or prior clinical data', 'Yes:', 'could not be explained by environmental factors or other treatment(s) being', 'administered', \"could not be explained by the patient's disease state or clinical condition\", 'follow a reasonable temporal sequence following the time of administration of the', 'dose of study drug or study procedure', 'resolve or improve after discontinuation of study drug or study procedure', 'reappear or worsen when dosing with study drug or study procedure is resumed', 'are known or suspected to be a response to the study drug or study procedure based', 'upon preclinical data or prior clinical data', 'NOTE: This list is not exhaustive.', 'Regeneron Pharmaceuticals, Inc.', 'Page 144 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}